Sino Biopharmaceutical (HKSE:01177) Common Stock : HK$453 Mil (As of Dec. 2023)

View and export this data going back to 2003. Start your Free Trial

What is Sino Biopharmaceutical Common Stock?

Sino Biopharmaceutical's quarterly common stock declined from Dec. 2022 (HK$463 Mil) to Jun. 2023 (HK$453 Mil) and declined from Jun. 2023 (HK$453 Mil) to Dec. 2023 (HK$453 Mil).

Sino Biopharmaceutical's annual common stock declined from Dec. 2021 (HK$509 Mil) to Dec. 2022 (HK$463 Mil) and declined from Dec. 2022 (HK$463 Mil) to Dec. 2023 (HK$453 Mil).

Sino Biopharmaceutical Common Stock Historical Data

The historical data trend for Sino Biopharmaceutical's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical Common Stock Chart

Sino Biopharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

309.85

493.02

508.69

463.32

453.50

Sino Biopharmaceutical Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Common Stock	Get a 7-Day Free Trial															508.69	486.39	463.32	453.50	453.50

Sino Biopharmaceutical Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Sino Biopharmaceutical (HKSE:01177) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (HKSE:01177) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

SBHMY:USA SBMFF:USA SMZ1:Germany

Address

1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG

Website

https://www.sinobiopharm.com

Sino Biopharmaceutical Co, or SBP, is one of the largest drugmakers in China, with CNY 27 billion revenue in 2021. Its four most important therapeutic areas are oncology, hepatitis, cardio-cerebral, and respiratory medicines. SBP's current portfolio is mostly generics, and some key drugs are facing severe price reductions. However, it also has a rich pipeline of early-to-market generics and biosimilars, especially in oncology and respiratory treatments.

Sino Biopharmaceutical (HKSE:01177) Headlines

No Headlines